Tempus AI (TEM) Total Equity: History & Chart

Tempus AI, Inc.(TEM)

Medical - Healthcare Information Services · Chicago, IL

$60.12-1.16 (-1.89%)

Delayed quote: Sep 10, 2026, 10:15 AM EDT

About Tempus AI, Inc.

Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.

Chicago, IL

3,800 employees

www.tempus.com

Healthcare / Medical - Healthcare Information Services

Sector: Healthcare
Industry: Medical - Healthcare Information Services
CEO: Eric Lefkofsky

View full financials

Total Equity

Basis: latest reported fiscal quarter. Source: stored company filings; unavailable inputs remain N/A.

The latest quarterly total equity is $444.93M with QoQ Growth of +6.85%. Total equity, also called shareholders' equity or book value, is assets minus liabilities.

Total Equity

TEM Total Equity

$444.93M

Reported quarterly total equity; no daily interpolation. Q2 FY2026 (2026-06-30): $444.93M.

+186.73% over 10Y

TEM P/B Ratio

Full P/B Ratio page

P/B Ratio

TEM P/B Ratio Chart

23.67

FMP quote market capitalization / matching reported stockholders equity Quote observation: 2026-09-10T14:15:24.000Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-09.

Quarterly Total Equity History

Period	Total Equity	QoQ Growth	YoY Growth
Q2 FY2026Period end 2026-06-30	$444.93M	+6.85%	+43.73%
Q1 FY2026Period end 2026-03-31	$416.40M	(15.25%)	+27.66%
Q4 FY2025Period end 2025-12-31	$491.33M	(3.25%)	+772.09%
Q3 FY2025Period end 2025-09-30	$507.82M	+64.05%	+845.18%
Q2 FY2025Period end 2025-06-30	$309.56M	(5.10%)	+215.07%
Q1 FY2025Period end 2025-03-31	$326.19M	+478.98%	N/A
Q4 FY2024Period end 2024-12-31	$56.34M	+4.86%	N/A
Q3 FY2024Period end 2024-09-30	$53.73M	(45.32%)	N/A
Q2 FY2024Period end 2024-06-30	$98.25M	N/A	N/A
Q1 FY2024Period end 2024-03-31	($1.47B)	(6.68%)	N/A
Q4 FY2023Period end 2023-12-31	($1.38B)	(4.34%)	N/A
Q3 FY2023Period end 2023-09-30	($1.32B)	N/A	N/A
Q4 FY2022Period end 2022-12-31	($1.13B)	(6.33%)	N/A
Q3 FY2022Period end 2022-09-30	($1.06B)	N/A	N/A
Q4 FY2021Period end 2021-12-31	($807.49M)	(9.22%)	(57.41%)
Q3 FY2021Period end 2021-09-30	($739.32M)	(11.54%)	N/A
Q2 FY2021Period end 2021-06-30	($662.85M)	N/A	N/A
Q1 FY2021Period end 2021-03-31	$220.96M	N/A	N/A
Q4 FY2020Period end 2020-12-31	($512.98M)	N/A	N/A

Growth uses unique fiscal quarters. Missing or ambiguous prior periods render N/A.